Oncotype DX Breast Cancer Test – Personalized Risk Assessment & Treatment Guidance

Oncotype DX Breast Cancer Test (ML) – Precision Medicine for Early-Stage Breast Cancer

The Oncotype DX Breast Cancer (ML) Test is a revolutionary genomic assay that analyzes the activity of 21 key genes in your tumor tissue to generate a Recurrence Score® (0–100), a powerful predictor of how likely your early-stage, hormone receptor-positive (HR+), HER2-negative breast cancer is to return after surgery.

More importantly, it reveals whether adding chemotherapy to hormone therapy will significantly reduce that risk — or if you can safely avoid the side effects of chemo without compromising your outcome.

Used globally as a standard of care, this test empowers you and your oncologist with personalized, evidence-based insights so you don’t have to guess about treatment. At Lab Tests Dubai, we coordinate seamlessly with hospitals and pathology labs across the UAE to ensure your tumor sample is processed through certified international laboratories where the Oncotype DX test is performed.

This isn’t just a test, it’s clarity at one of life’s most uncertain moments.

Why You Need This Test

You need the Oncotype DX Test if:

• You’ve been diagnosed with early-stage, node-negative or limited node-positive, HR+, HER2-negative breast cancer
• Your doctor recommends hormone therapy but is unsure about adding chemotherapy
• You want to avoid unnecessary chemo and its long-term side effects (fatigue, neuropathy, heart issues, infertility)
• You’re seeking scientific proof to guide your treatment decisions
• You value precision medicine tailored to your tumor biology

This test answers the critical question: “Do I really need chemotherapy?” — giving you confidence in your treatment plan.

Natural Production (Clarification: Gene Expression & Cancer)

Your body naturally produces proteins regulated by genes involved in cell growth and repair. In some breast cancers, certain genes become overactive or underactive — driving tumor behavior beyond what traditional tests can predict.

The Oncotype DX Test does not detect mutations, but measures the expression levels (activity) of 21 genes related to:

• Cancer proliferation
• Hormone signaling
• Invasion potential
• HER2 pathway
• Reference genes

These expression patterns are combined into a Recurrence Score®, which reflects the biological aggressiveness of your cancer, helping determine if chemotherapy adds meaningful benefit.

How to Prepare for the Test

No patient preparation required — the test uses existing tumor tissue:

• Sample Requirements:

• FFPE Tumor Block or Slides: From lumpectomy or mastectomy

• Minimum of 10 unstained slides (plus H&E-stained slide for review)

• Must show invasive carcinoma (≥30% tumor cells preferred)

• Clinical Information Required:

• Completed Test Request Form (TRF)

• Pathology report confirming ER+, PR+, HER2-negative status

• Patient consent form

• Clinical details: tumor size, grade, nodal status

Our team coordinates secure shipping to the licensed international lab (Exact Sciences) with full tracking and compliance support.

Test Overview